Date
|
Update
|
13 February 2024 - 12 March 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3949 |
13 February 2024
|
In progress. Scoping commencing |
18 August 2022
|
Suspended. As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949].
For information the company have advised that they will not be making a submission. Therefore, in collaboration with the company, NICE has suspended this evaluation from its current work programme.
As this evaluation has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |